Jobs / United States / Glaxosmithkline LLC
SERM Senior Medical Director, Oncology
Glaxosmithkline LLC · 🇺🇸 3 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Find out more: Our approach to R&D Position Summary As SERM Senior Medical Director, Oncology, you will lead clinical safety and pharmacovigilance strategy for oncology assets within Global Safety. You will oversee rigorous review, interpretation and communication of safety data, ensuring timely identification, escalation and management of safety issues. Working in a global, cross-functional matrix, you will collaborate with senior governance and partner teams to drive evidence-based safety decisions. You will also mentor SERM colleagues, strengthening safety and risk-management capabilities and supporting their development across the portfolio. Responsibilities • Provide expert leadership in clinical safety and pharmacovigilance for oncology assets, including signal evaluation, benefit–risk assessment, regulatory submissions and proactive risk-management strategies. • Oversee the review, interpretation and communication of safety data; identify, escalate and manage safety issues through established safety governance forums. • Develop and implement safety strategies, policies and processes aligned with Global Safety operational and strategic plans. • Coach and mentor medical and scientific colleagues in SERM in signal evaluation, risk management, and preparation of regulatory safety deliverables. • Lead within a global, cross-functional matrix, building strong collaborative relationships and influencing internal and external stakeholders on safety topics. • Lead or oversee SERM safety input into due diligence and other key strategic activities, ensuring safety perspectives shape decision-making. Why You? Basic Qualification We are seeking professionals with the following required skills and qualifications to help us achieve our goals: • Medical degree, with completion of a formal postgraduate clinical training, residency or specialty training • Experience in the pharmaceutical or biotechnology industry working in pharmacovigilance or drug safety. • Experience in clinical safety and pharmacovigilance activities, including evidence generation, benefit–risk assessment, causality assessment and evaluation of safety signals. • Experience developing and executing safety strategies for products in clinical development. • Experience with international pharmacovigilance requirements and drug development and approval processes (for example ICH, GVP modules, CIOMS initiatives). • Experience of leading large matrix organizations and cross-functional teams. Preferred Qualification • Experience developing and executing safety strategies for products in clinical development, preferably in Oncology • Proven record of high-quality, timely decision-making and creative problem-solving in complex or critical safety situations. • Experience leading or contributing to safety governance activities, such as safety advisory panels and senior governance committees. • Experience with successful global regulatory filings (e.g., IND/CTA, NDA/BLA, and EMA/MHRA MAAs). • Recognised expertise in pharmacovigilance regulations and methodologies, and experience contributing to external pharma